Comparison of clinically relevant oncolytic virus platforms for enhancing T-cell therapy of solid tumors

Victor Cervera-Carrascon, Dafne C.A. Quixabeira, Riikka Havunen, Joao M. Santos, Emma Kutvonen, James H.A. Clubb, Mikko Siurala, Camilla Heiniö, Sadia Zafar, Teija Koivula, Dave Lumen, Marjo Vaha, Arturo Garcia-Horsman, Anu J. Airaksinen, Suvi Sorsa, Marjukka Anttila, Veijo Hukkanen, Anna Kanerva, Akseli Hemminki

Research output: Contribution to journalArticleScientificpeer-review


Despite some promising results, the majority of patients do not benefit from T-cell therapies, as tumors prevent T-cells from entering the tumor, shut down their activity, or downregulate key antigens. Due to their nature and mechanism of action, oncolytic viruses have features that can help overcome many of the barriers currently facing T-cell therapies of solid tumors. This study aims to understand how four different oncolytic viruses (adenovirus, vaccinia virus, herpes simplex virus and reovirus) perform in that task. For that purpose, an immunocompetent in vivo tumor model featuring adoptive tumor-infiltrating lymphocyte (TIL) therapy was used. Tumor growth control (p
Original languageEnglish
JournalMolecular Therapy - Oncolytics
Publication statusPublished - 19 Mar 2020
MoE publication typeA1 Journal article-refereed

Fields of Science

  • oncolytic virus
  • immunotherapy
  • T-cell therapy
  • tumor microenvironment
  • solid tumor
  • 3122 Cancers

Cite this